Survey of oncologists finds knowledge gap on medical marijuana
As more states legalize medical marijuana, two key groups — researchers whose job is it to understand its benefits and drawbacks, and physicians charged with advising potential users — are struggling to catch up with policymakers.
Ilana Braun, an assistant professor of psychiatry at Harvard Medical School and chief of the division of adult psychosocial oncology at the Dana-Farber Cancer Institute, led a survey of cancer physicians around the country, exploring their attitudes and actions on medical marijuana.
The survey was sent to 400 oncologists, with a 63 percent response rate. We asked Braun to outline her findings, which were published last month in the Journal of Clinical Oncology.
Stories you may be interested in
PTSD: Is There Any Relief?
In honor of PTSD awareness month, let’s take a look at the debilitating mental health condition and how medical marijuana could help.Post-traumatic stress disorder is a mental health condition caused by witnessing or experiencing a traumatic event. It is understandable for one to be taken aback and impacted by a traumatic event, but if specific…
Read More 
Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease
A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More 
European Parliament Passes Cannabis Resolution, Joins WHO In Supporting Medical Marijuana
Following reports about the World Health Organization (WHO) recommending a rescheduling of cannabis and several of its key components under international drug treaties, the European Parliament voted on Wednesday on a resolution that would help advance medical cannabis in the countries that form the European Union. Read the full story here.
Read More 
More Treatment Options, Better Patient Outcomes
As more states start to pass medical marijuana legislation, patients benefit from having more options available to them regarding their treatment. In fact, a recent study from Columbia University’s Irving Medical Center found that, “States with active medical marijuana laws saw certain opioid prescription rates drop nearly 20 percent compared to states without medical marijuana…
Read More 
Cannabis improves symptoms of Crohn’s disease despite having no effect on gut inflammation
In the first study of its kind, cannabis oil has been shown to significantly improve the symptoms of Crohn’s disease and the quality of life of sufferers but, contrary to previous medical thinking, has no effect on gut inflammation. In a randomised, placebo-controlled study, researchers from Israel have shown that cannabis can produce clinical remission…
Read More 
Research shows cannabis can lower opioid dosage, but studies are preliminary
Larson cited one statistic to justify his bill: “Studies have shown up to 75% reduction in opioid dosage for medical cannabis users” The intersection of medical cannabis and opioid use as treatments for chronic pain is an emerging field of research as more states loosen regulations on medical and recreational use of marijuana. But does…
Read More